|
 
Last update: |
 |
|
|
01-Oct-2015
|
 |
|
|
Arch Hellen Med, 32(5), September-October 2015, 535-545 REVIEW Weekly antidiabetic treatment with GLP-1 agonists: Efficacy and safety A.K. Papazafiropoulou, A. Melidonis |
Targeting the incretin system with glucagon-like peptide (GLP)-1 receptor agonists has become an important therapeutic approach for treating type 2 diabetes mellitus (DM). Recently, weekly administration of GLP-1 agonists has been shown to improve glycemic control while reducing body weight in patients with type 2 DM. With these agents the incidence of hypoglycemia is relatively low, because of their glucose-dependent mechanism of action. The main adverse events that have been observed with this treatment are nausea and vomiting. Currently, four weekly GLP-1 agonists are either available or currently being developed. This is a review of the efficacy and safety of weekly GLP-1 receptor agonists and their impact on the management of patients with type 2 DM.
Key words: Albiglutide, Dulaglutide, Exenatide, Semaglutide, Taspoglutide.
